I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ACTRIMS Forum 2022

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Feb 24 / Roche and Genentech
Long-term Efficacy and Safety of Satralizumab▼ in Adults with AQP4-IgG-seropositive Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the phase 3 SAkura studies
The long-term efficacy and safety of satralizumab▼ was assessed in adults with AQP4-IgG seropositive NMOSD from the SAkuraSky and SAkuraStar studies. The efficacy of satralizumab ▼(± IST) was sustained over more than 3.5 years; high proportions of patients remained free from relapse, severe relapse, or worsening disease. Additionally, the safety profile of satralizumab▼ (± IST) was sustained with up to 7 years of follow-up, with no new safety concerns.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 24 / Roche and Genentech
SAkuraBONSAI: A prospective, open-label study of satralizumab▼ Investigating novel imaging, biomarker, and clinical outcomes in patients with AQP4-IgG-seropositive NMOSD
SAkuraBONSAI will use comprehensive longitudinal, clinical, imaging and biomarker assessments to evaluate NMOSD disease pathology and progression, treatment response, and the mechanism of action of satralizumab▼ in AQP4-IgG seropositive NMOSD patients who are treatment-naïve or have failed prior rituximab treatment.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 24 / Roche and Genentech
Watch Dr Exuzides discuss Testing a Claims-Based Algorithm to Identify Patients with Neuromyelitis Optica Spectrum Disorder
This video is about using structured cognitive interviews with neurologists experienced in treating NMOSD, a healthcare claims-based algorithm was developed to identify patients with NMOSD from claims data. In this analysis, the performance of the algorithm was tested using notes, medications, and billing codes on a sample of physician-diagnosed patients with NMOSD, MS or MOGAD.